Sustained Complete Response to Brigatinib in a Young ALK+ NSCLC Patient

Managing Resistance in ALK-Positive Lung Cancer – Case Applying Precision Oncology Approach
In this expert case presentation, Dr. Akhil Kapoor shares the journey of a young, non-smoking patient with ALK-positive non-small cell lung cancer who developed resistance to alectinib due to an ALK I1171N mutation.
Through repeat molecular testing, the treatment was precisely adapted to brigatinib—leading to a remarkable and durable complete response, including CNS disease control.
This case highlights the importance of repeat molecular testing for guiding treatment sequencing and demonstrates brigatinib’s effectiveness against specific ALK resistance mutations, underscoring the role of precision oncology in personalized therapy for ALK-positive NSCLC.
Key takeaway: Not all ALK inhibitors are interchangeable; treatment must be mutation-specific. Individualised approach is important